Clinical trials: Advanced Gastric Carcinoma
Gastric Cancer
High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving higher doses may kill more tumor cells.
- Trial name
- NCT00002722
- Testing
- cisplatin, fluorouracil, leucovorin calcium
- Volunteers
- 135 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
This study evaluates the change of quality of life, treatment decision and utilization of health care depending on the use of palliative care in advanced cancer patients by a prospective cohort study.
- Conditions
- Stage IV Breast Cancer, Stage IV Pancreatic Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer
- Trial name
- NCT03222258
- Testing
- Early palliative care, Routine hospice care
- Where
- 15 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Seoul National University Hospital
Uterine Cervical Neoplasms, Surgery
Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
This study aims to collect data of patients with Gastric-type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of Gastric-type Endocervical Adenocarcinoma, and…
- Conditions
- Uterine Cervical Neoplasms, Surgery, Therapy, Locally Advanced Cervical Carcinoma
- Trial name
- NCT06897306
- Testing
- surgery
- Where
- China
- Volunteers
- 317 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastric Cancer
CT Body Composition Enhances Survival Risk Stratification
Gastric carcinoma remains the fifth most common malignancy and the second leading cause of cancer-related mortality worldwide. For patients with locally advanced disease, standard treatment includes radical gastrectomy followed…
- Trial name
- NCT07109271
- Where
- Taiwan
- Volunteers
- 227 people
- Sponsor
- Chang Gung Memorial Hospital
Gastric Cancer
Multivisceral Resections for Locally Advanced Gastric Cancer
The goal of this observational study is to assess whether the postoperative course and survival of patients subject to multivisceral resections for locally advanced gastric cancer (cT4b) were affected by the extent of surgery.
- Trial name
- TOCCATA (NCT06103435)
- Testing
- Extent od surgical resection
- Where
- Poland
- Volunteers
- 1,476 people
- Sponsor
- Jagiellonian University
Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced…
- Conditions
- Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
- Trial name
- YOUNG-NEOS (NCT07018063)
- Testing
- nab-paclitaxel, oxaliplatin, S-1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- zhoujing
Stomach Neoplasms
Randomized Controlled Trials on Laparoscopic No. 14v LNS Dissection
The purpose of this study is to explore the short-term, long-term and oncological outcomes of laparoscopic No. 14v lymph node dissection in advanced lower third gastric cancer.
- Trial name
- NCT02789891
- Testing
- D2 lymphadenectomy including No. 14v, lymphadenectomy excluding No. 14v
- Volunteers
- 326 people
- Sponsor
- Fujian Medical University
Gastric Cancer
Safety and Efficacy of Trastuzumab BS
To confirm the safety and efficacy of this drug under the actual use
- Trial name
- NCT04181333
- Testing
- TRASTUZUMAB BS
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Pfizer
Gastric Cancer, Peritoneal Metastases
Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer
Data demonstrating the efficacy of PIPAC in patients with regionally advanced gastric cancer with positive peritoneal cytology and/or minimal peritoneal disease is limited due to the relatively recent development of this…
- Conditions
- Gastric Cancer, Peritoneal Metastases, Chemotherapy Effect
- Trial name
- SPECTRA (NCT05318794)
- Testing
- Doxorubicin and Cisplatin
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College London
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study.
- Trial name
- OASIS (NCT04503967)
- Testing
- Anlotinib Hydrochloride With Nivolumab
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Gastric Cancer
Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer
The primary end-point of this study is to evaluate the objective response rates, and the secondary end-points are overall survival, progression-free survival and safety profile of low-dose RAD001 (everolimus) plus cisplatin and…
- Trial name
- NCT00632268
- Testing
- RAD001; Cisplatin; 5-FU; Leucovorin
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Gastric Cancer
Surgery for Obstructed Gastric Carcinoma
The goal of this clinical trial is to find the best treatment for obstructed gastric carcinoma in gastric cancer patients. It will include all patients with obstructed gastric cancer with different ages and sex who consented to…
- Trial name
- NCT07435025
- Testing
- palliative gastric resection, palliative bypass
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- Zagazig University
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Gastric Cancer
A Benefit Population Atlas of nICT Versus nCT for LAGC
The purpose of this observational study is to evaluate the impact of different neoadjuvant therapies on patients with locally advanced gastric cancer.
- Trial name
- NCT07098104
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 291 people
- Sponsor
- Cheng Chen
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06902545
- Testing
- zolbetuximab
- Where
- 15 sites in South Korea
- Volunteers
- 377 people
- Sponsor
- Astellas Pharma Korea, Inc.
Advanced Gastric Cancer
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
Because well-designed, randomized, controlled clinical trials are lacking in patients with advanced gastric cancer (AGC), and because randomly allocating patients to treatments that do not accord with their preferences may…
- Trial name
- NCT00821990
- Testing
- Chemotherapy, Best supportive care
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Gastric Cancer
Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy
HMDLS, based on hematological markers, could effectively distinguish the long-term efficacy of AGC patients after NAT. The predictive performance of nomogram-HMDLS was better than ypTNM stage, achieving better prognostic…
- Trial name
- NCT06573307
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Chang-Ming Huang, Prof.